SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: An observational survey

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 4, 2008, Pages 267-271

  Bertrand, Yves ^a   Mechinaud, Françoise ^b   Brethon, Benoit ^c   Mialou, Valerie ^a   Auvrignon, Anne ^d   Nelken, Brigitte ^e   Notz Carrère, Anne ^f   Plantaz, Dominique ^g   Patte, Catherine ^h   Urbieta, Marisol ⁱ   Baruchel, André ^c   Leverger, Guy ^d  

^a HÔPITAL DEBROUSSE   (France)

^b HÔTEL DIEU   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d Service d'Hematologie   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f HÔPITAL PELLEGRIN   (France)

^g CHU La Tronche and University   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ SANOFI   (France)

Author keywords

Hyperuricemia; Pediatric; Rasburicase; Tumor lysis syndrome

Indexed keywords

RASBURICASE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; CANCER PATIENT; CHILD; CLINICAL PRACTICE; CLINICAL TRIAL; FEMALE; HEALTH CENTER; HEALTH SURVEY; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT CARE; PATIENT CODING; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; TREATMENT DURATION; TUMOR LYSIS SYNDROME; VALIDATION STUDY;

EID: 41949086954     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318162bd41     Document Type: Article

References (24)

1. Bishop MR, Coccia PF. Tumor lysis syndrome. In: Abeloff A, ed. Clinical Oncology. 2nd ed. New York: Churchill Livingstone; 2000:750-754.
2. Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol. 2000;27:322-334.
3. Jeha S. Tumor lysis syndrome. Semin Hematol. 2001;38:4-8.
4. Jones DP, Mahmoud H, Chesnay RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol. 1995;9:206-212.
5. Castro MP, VanAuken J, Spencer-Cisek P, et al. Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature. Cancer. 1999;85:1055-1059.
6. Locatelli F, Rossi F. Incidence and pathogenesis of tumor lysis syndrome. Contrib Nephrol. 2005;147:61-68.
7. Arrambide K, Toto RD. Tumor lysis syndrome. Semin Nephrol. 1993;13:273-280.
8. Chasty RC, Liu-Yin JA. Acute tumour lysis syndrome. Br J Hosp Med. 1993;49:488-492.
9. Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma. 2003;44:77-83.
10. Cheson BD, Dutcher BS. Managing malignancy-associated hyperuricemia with rasburicase. J Support Oncol. 2005;3:117-124.
11. Andreoli SP, Clark JH, McGuire WA, et al. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr. 1986;109:292-298.
12. Conger JD, Falk SA. Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest. 1977;59:786-793.
13. Holdsworth MT, Nguyen P. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome. Am J Health Syst Pharm. 2003;60:2213-2222.
14. Jeha S, Pui CH. Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome. Contrib Nephrol. 2005;147:69-79.
15. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998-3003.
16. Pui CH, Jeha S, Irwin D, et al. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia. 2001;15:1505-1509.
17. Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer. 2003;98:1048-1054.
18. Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy- associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005;19:34-38.
19. Patte C, Sakiroglu C, Ansoborlo S, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pediatrique LMB89 protocol. Ann Oncol. 2002;13:789-795.
20. Atra A, Gerrard M, Hobson R, et al. Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL). Results of the UKCCSG 9003 protocol. Br J Cancer. 1998;77:2281-2285.
21. Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol. 1996;14:1252-1261.
22. Mahmoud HH, Leverger G, Patte C, et al. Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer. 1998;77:18-20.
23. Wolf G, Hegewisch-Becker S, Hossfeld DK, et al. Hyperuricemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy? Am J Kidney Dis. 1999;34:E20.
24. Liu CY, Sims-McCallum RP, Schiffer CA. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leukemia Res. 2005;4:163-165.